These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35927373)

  • 21. Understanding and interpreting confidence and credible intervals around effect estimates.
    Hespanhol L; Vallio CS; Costa LM; Saragiotto BT
    Braz J Phys Ther; 2019; 23(4):290-301. PubMed ID: 30638956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient simulation of clinical target response surfaces.
    Lill D; Kümmel A; Mitov V; Kaschek D; Gobeau N; Schmidt H; Timmer J
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):512-523. PubMed ID: 35199969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A tutorial on uncertainty propagation techniques for predictive microbiology models: A critical analysis of state-of-the-art techniques.
    Akkermans S; Nimmegeers P; Van Impe JF
    Int J Food Microbiol; 2018 Oct; 282():1-8. PubMed ID: 29885972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothesis testing, statistical power, and confidence limits in the presence of epistemic uncertainty.
    Hofer E
    Health Phys; 2007 Mar; 92(3):226-35. PubMed ID: 17293694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A guide to representing variability and uncertainty in biodiversity indicators.
    Rowland JA; Bland LM; James S; Nicholson E
    Conserv Biol; 2021 Oct; 35(5):1669-1682. PubMed ID: 33486826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.
    Hill-McManus D; Marshall S; Liu J; Willke RJ; Hughes DA
    Clin Pharmacol Ther; 2021 Jul; 110(1):49-63. PubMed ID: 32936931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
    Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
    Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on Holmes et al. (2007): resolving the debate on when extinction risk is predictable.
    Ellner SP; Holmes EE
    Ecol Lett; 2008 Aug; 11(8):E1-5. PubMed ID: 18638300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Real-World Data: A Case Study on Valproic Acid.
    Soeorg H; Sverrisdóttir E; Andersen M; Lund TM; Sessa M
    Clin Pharmacol Ther; 2022 Jun; 111(6):1278-1285. PubMed ID: 35263452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automatic data binning for improved visual diagnosis of pharmacometric models.
    Lavielle M; Bleakley K
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):861-71. PubMed ID: 22042498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reporting a population pharmacokinetic-pharmacodynamic study: a journal's perspective.
    Jamsen KM; McLeay SC; Barras MA; Green B
    Clin Pharmacokinet; 2014 Feb; 53(2):111-22. PubMed ID: 24327237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An illustration of the effect of various sources of uncertainty on DNA likelihood ratio calculations.
    Taylor D; Bright JA; Buckleton J; Curran J
    Forensic Sci Int Genet; 2014 Jul; 11():56-63. PubMed ID: 24667729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying the uncertainty in model parameters using Gaussian process-based Markov chain Monte Carlo in cardiac electrophysiology.
    Dhamala J; Arevalo HJ; Sapp J; Horácek BM; Wu KC; Trayanova NA; Wang L
    Med Image Anal; 2018 Aug; 48():43-57. PubMed ID: 29843078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
    Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
    Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of uncertainty about population parameters on pharmacodynamics-based prediction of clinical trial power.
    Kraiczi H; Frisén M
    Contemp Clin Trials; 2005 Apr; 26(2):118-30. PubMed ID: 15837435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Causal inference accounting for unobserved confounding after outcome regression and doubly robust estimation.
    Genbäck M; de Luna X
    Biometrics; 2019 Jun; 75(2):506-515. PubMed ID: 30430543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncertainty and variability in risk from trophic transfer of contaminants in dredged sediments.
    Linkov I; von Stackelberg KE; Burmistrov D; Bridges TS
    Sci Total Environ; 2001 Jul; 274(1-3):255-69. PubMed ID: 11453301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Model confidence bounds for variable selection.
    Li Y; Luo Y; Ferrari D; Hu X; Qin Y
    Biometrics; 2019 Jun; 75(2):392-403. PubMed ID: 30648746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.